B Rossetti1, S Di Giambenedetto2, C Torti3, M C Postorino3, G Punzi4, F Saladini5, W Gennari6, V Borghi7, L Monno8, A R Pignataro9, E Polilli10, M Colafigli2, A Poggi11, S Tini12, M Zazzi5, A De Luca1,5. 1. Infectious Diseases Unit, University Hospital of Siena, Siena, Italy. 2. Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy. 3. Infectious Diseases Unit, Catanzaro, Italy. 4. Virology, Bari Hospital, Bari, Italy. 5. Department of Medical Biotechnologies, University of Siena, Siena, Italy. 6. Virology, Modena Hospital, Modena, Italy. 7. Infectious Diseases Unit, Modena Hospital, Modena, Italy. 8. Infectious Diseases Unit, Bari Hospital, Bari, Italy. 9. Humanitas San Raffaele, Milan, Italy. 10. Virology, Pescara Hospital, Pescara, Italy. 11. Infectious Diseases Unit, S. Maria Annunziata Hospital, Firenze, Italy. 12. Medicine Department, Città di Castello, Italy.
Abstract
OBJECTIVES: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. METHODS: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. RESULTS: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169-521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1-5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93-4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75-0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40-0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91-0.99; P = 0.02). CONCLUSIONS: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.
OBJECTIVES: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. METHODS:HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. RESULTS: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169-521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1-5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93-4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75-0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40-0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91-0.99; P = 0.02). CONCLUSIONS: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.
Authors: Giovanni Lorenzin; Franco Gargiulo; Arnaldo Caruso; Francesca Caccuri; Emanuele Focà; Anna Celotti; Eugenia Quiros-Roldan; Ilaria Izzo; Francesco Castelli; Maria A De Francesco Journal: Microorganisms Date: 2019-12-23
Authors: Vlad Novitsky; Jon Steingrimsson; Fizza S Gillani; Mark Howison; Su Aung; Matthew Solomon; Cindy Y Won; Amy Brotherton; Rajeev Shah; Casey Dunn; John Fulton; Thomas Bertrand; Anna Civitarese; Katharine Howe; Theodore Marak; Philip Chan; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor Journal: Open Forum Infect Dis Date: 2021-12-07 Impact factor: 4.423
Authors: Mafalda N S Miranda; Marta Pingarilho; Victor Pimentel; Maria do Rosário O Martins; Rolf Kaiser; Carole Seguin-Devaux; Roger Paredes; Maurizio Zazzi; Francesca Incardona; Ana B Abecasis Journal: Front Microbiol Date: 2022-04-13 Impact factor: 5.640
Authors: Davide F Bavaro; Andrea De Vito; Giuseppe Pasculli; Yagai Bouba; Laura Magnasco; Rachele Pincino; Francesco Saladini; Rossana Lattanzio; Romina Corsini; Serena Arima; Maurizio Zazzi; Francesca Incardona; Barbara Rossetti; Antonia Bezenchek; Borghi Vanni; Antonio Di Biagio Journal: J Med Virol Date: 2022-04-09 Impact factor: 20.693
Authors: Madita Schlösser; Vladimir V Kartashev; Visa H Mikkola; Andrey Shemshura; Sergey Saukhat; Dmitriy Kolpakov; Alexandr Suladze; Tatiana Tverdokhlebova; Katharina Hutt; Eva Heger; Elena Knops; Michael Böhm; Veronica Di Cristanziano; Rolf Kaiser; Anders Sönnerborg; Maurizio Zazzi; Marina Bobkova; Saleta Sierra Journal: Viruses Date: 2020-04-22 Impact factor: 5.048